Reading the tape
NASDAQ: BLLN
BillionToOne, Inc.
Healthcare · Medical - Diagnostics & Research
Market Cap
$3.32B
52w High
$138.70
52w Low
$61.96
P/E
1,016.44
Volume
697.37K
Outstanding Shares
45.99M
Price vs Fundamentals
Why The Stock Is Moving
Likely multiple compressionModerate confidence
Note: The most recent financial data is over 3 months old. Metrics shown may not reflect the latest reporting period.
1Y Price: -33.8%Revenue (YoY): 99.97%FCF (YoY): 133.59%
What changed
The stock fell 33.8% over the last year. Revenue grew 99.97% year over year. Operating margin moved from -30.9% to 5.25%. Free cash flow grew 133.59% year over year.
What the market seems to be pricing
Visible fundamentals weakened far less than the stock price. The market appears to be discounting durability, risk, or trust rather than just the latest reported numbers.
What would invalidate this read
This read changes if operating margin (currently 5.25%) continues to decline, or if revenue growth turns negative. The bull case requires the business to hold its current trajectory.
Company profile
BillionToOne, Inc., a precision diagnostics company, quantifies biology to create molecular diagnostics.
CEOOguzhan Atay
SectorHealthcare
IndustryMedical - Diagnostics & Research
Employees620
IPO dateNov 6, 2025
Valuation
Forward P/E—
EV/EBITDA209.80
Enterprise value$3.36B
Stock splits
No stock splits recorded for this ticker.
Profitability & growth
Revenue growth113.09%
Gross margin68.32%▲28.83%vs FY2024
Operating margin5.25%▲117.00%vs FY2024
ROE1.55%▲106.27%vs FY2024
Analyst consensus
RatingBuy
Target price$130.33▲80.71%
3
Buy
1
Hold
0
Sell
Analyst ratings tend to be lagging indicators. Use as one signal among many.
Earnings
Full quarter-by-quarter history of actuals vs estimates. Switch into compare mode to inspect one metric year-over-year.
Next report
May 6, 2026
Q2 FY26 · EPS est $0.03 · Revenue est $97.14M
View